




Contents lists available at ScienceDirect

# International Journal for Parasitology: Drugs and Drug Resistance

journal homepage: [www.elsevier.com/locate/ijpddr](http://www.elsevier.com/locate/ijpddr)

## Quantitative tests of albendazole resistance in *Caenorhabditis elegans* beta-tubulin mutants

J.B. Collins<sup>a,1</sup>, Skyler A. Stone<sup>b,1</sup>, Emily J. Koury<sup>b</sup>, Anna G. Paredes<sup>b</sup>, Fiona Shao<sup>b</sup>, Crystal Lovato<sup>b</sup>, Michael Chen<sup>b</sup>, Richelle Shi<sup>b</sup>, Anwyn Y. Li<sup>b</sup>, Isa Candal<sup>b</sup>, Khadija Al Moutaa<sup>b</sup>, Nicolas D. Moya<sup>a</sup>, Erik C. Andersen<sup>a,\*</sup>

<sup>a</sup> Department of Biology, Johns Hopkins University, Baltimore, MD, 21218, USA

<sup>b</sup> Department of Molecular Biosciences, Northwestern University, Evanston, IL, 60208, USA

### ARTICLE INFO

#### Keywords:

Beta-tubulin  
Benzimidazole  
Anthelmintic resistance  
*C. elegans*

### ABSTRACT

Benzimidazole (BZ) anthelmintics are among the most important treatments for parasitic nematode infections in the developing world. Widespread BZ resistance in veterinary parasites and emerging resistance in human parasites raise major concerns for the continued use of BZs. Knowledge of the mechanisms of resistance is necessary to make informed treatment decisions and circumvent resistance. Benzimidazole resistance has traditionally been associated with mutations and natural variants in the *C. elegans* beta-tubulin gene *ben-1* and orthologs in parasitic species. However, variants in *ben-1* alone do not explain the differences in BZ responses across parasite populations. Here, we examined the roles of five *C. elegans* beta-tubulin genes (*tbb-1*, *mec-7*, *tbb-4*, *ben-1*, and *tbb-6*) in the BZ response as well as to determine if another beta-tubulin acts redundantly with *ben-1*. We generated *C. elegans* strains with a loss of each beta-tubulin gene, as well as strains with a loss of *tbb-1*, *mec-7*, *tbb-4*, or *tbb-6* in a genetic background that also lacks *ben-1*. We found that the loss of *ben-1* conferred the maximum level of resistance following exposure to a single concentration of albendazole, and the loss of a second beta-tubulin gene did not alter the level of resistance. However, additional traits other than larval development could be affected by the loss of additional beta-tubulins, and the roles of other beta-tubulin genes might be revealed at different albendazole concentrations. Therefore, further work is needed to fully define the possible roles of other beta-tubulin genes in the BZ response.

### 1. Introduction

Parasitic nematode infections are among the most common infectious diseases of humans and pose significant health and socioeconomic risks for endemic regions. Upwards of 1.5 billion people are estimated to be infected with at least one parasitic nematode species globally, with infections causing anemia, impaired cognitive development, reduced growth, diarrheal disease, intestinal obstructions, and lymph edema (Salikin et al., 2020). Anti-helminth drugs, or anthelmintics, are used in endemic areas to control infections and limit adverse health effects caused by parasitic nematodes. Anthelmintics are often delivered through mass drug administration (MDA) programs designed to deliver essential medicines to regions with infected populations.

One of the most common anthelmintics delivered in MDA programs

is albendazole (ABZ), a drug belonging to the benzimidazole (BZ) class of anthelmintics. The BZ drug class is included in many MDA programs because of its broad-spectrum activity, capable of treating a wide variety of intestinal helminths, as well as being safe and affordable to easily deliver to large populations (Banerjee et al., 2023). Studies of the mode of BZ action have found that they inhibit the polymerization of microtubules by targeting beta-tubulin (Hastie and Georgopoulos, 1971; Sheir-Neiss et al., 1978). A study of BZ response in the free-living model nematode *Caenorhabditis elegans* found that larvae exposed to BZs were developmentally impaired and uncoordinated in locomotion (Chalfie and Thomson, 1982). Subsequent experiments showed that animals with loss-of-function mutations in the beta-tubulin gene *ben-1* were found to exhibit wild-type growth and movement in the presence of BZs (Driscoll et al., 1989). Wild-type growth, despite the loss of *ben-1*, is thought to be

\* Corresponding author. Department of Biology, Johns Hopkins University, Bascom UTL 383, 3400 North Charles St., Baltimore, MD, 21218, USA.

E-mail address: [erik.andersen@gmail.com](mailto:erik.andersen@gmail.com) (E.C. Andersen).

<sup>1</sup> Equal contribution.

<https://doi.org/10.1016/j.ijpddr.2024.100556>

Received 11 April 2024; Received in revised form 5 July 2024; Accepted 6 July 2024

Available online 9 July 2024

2211-3207/© 2024 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

possible because another beta-tubulin gene acts redundantly and compensates for the loss of *ben-1*. The *C. elegans* genome contains five additional beta-tubulin genes (*tbb-1*, *tbb-2*, *mec-7*, *tbb-4*, and *tbb-6*) that are differentially expressed in various tissues and are thought to supply beta-tubulin function when *ben-1* is lost (Hurd, 2018).

Orthologs of *ben-1* were found to be the target of BZs in parasitic nematodes. A beta-tubulin gene (*tbb-isotype-1*) from *Haemonchus contortus*, a small-ruminant parasite, was found to rescue BZ susceptibility when expressed in a *C. elegans* strain that lacked *ben-1* (Kwa et al., 1993, 1994, 1995). Unlike *C. elegans*, the *H. contortus* genome contains only four genes encoding beta-tubulins (*tbb-isotype-1*, *tbb-isotype-2*, *tbb-isotype-3*, and *tbb-isotype-4*) (Saunders et al., 2013). A smaller complement of beta-tubulin genes, combined with expression differences between each of the four genes has led to the conclusion that loss of *tbb-isotype-1* likely causes lethality, indicating that BZ resistance in parasites is probably dependent on altered function variants in *tbb-isotype-1* (Saunders et al., 2013). However, parasitic nematodes currently lack the genetic tools, such as genome editing, to validate resistance genes using targeted mutations. Exploration of anthelmintic resistance is dependent on *C. elegans* as a complement to research in parasites, and a cycle of discovery has been proposed to explore and validate the mechanisms of BZ resistance using both free-living and parasitic nematodes (Wit et al., 2021).

Anthelmintic resistance is a major concern in the control of parasites. Resistance to the BZ drug class has become nearly ubiquitous in many nematode species of veterinary importance and is now an emerging problem in nematode infections of humans (Kaplan, 2004; Howell et al., 2008; Krücken et al., 2017). The development of resistance to BZs makes the control of infections difficult and costly. To address the emergence of BZ resistance, it is necessary to understand the underlying genetics contributing to resistance. After suspected resistance-associated variants are identified in parasites, they can be validated in *C. elegans* using CRISPR-Cas9 genome editing. Studies of BZ resistance have identified non-synonymous variants at codons 134, 167, 198, and 200 of *ben-1* orthologs in parasites (Kwa et al., 1994; Avramenko et al., 2019; Mohammedsalih et al., 2020; Venkatesan et al., 2023). Every known beta-tubulin variant associated with BZ resistance in parasitic nematodes has been shown to cause resistance in *C. elegans* by the introduction of the variant into the *ben-1* gene (Kwa et al., 1994; Kitchen et al., 2019; Dilks et al., 2020, 2021; Venkatesan et al., 2023). These variants in parasite beta-tubulin genes are hypothesized to alter a putative BZ binding site, preventing BZs from inhibiting beta-tubulin, preserving the normal formation of microtubules, and allowing nematodes to survive and develop normally in the presence of BZ treatment.

Despite the validation of variants in *ben-1* orthologs as a mechanism of resistance to BZs, *ben-1* is not the only gene involved in BZ resistance. Genome-wide association studies in wild populations of *C. elegans* have identified multiple genomic loci independent of *ben-1* that are associated with BZ resistance (Hahnel et al., 2018; Zamanian et al., 2018). Fully understanding the genetics of resistance is necessary to inform strategic decisions that improve the efficacy of existing treatments, as well as lead to the development of new treatments and control strategies. Thus, it is imperative to identify all genes associated with BZ resistance. Here, we explored how the loss of each beta-tubulin gene affects BZ resistance in *C. elegans*. The gene *ben-1* has been extensively studied and confers the greatest level of BZ resistance. However, the roles of and potential redundancies with the other *C. elegans* beta-tubulin genes (*tbb-1*, *tbb-2*, *mec-7*, *tbb-4*, and *tbb-6*) in BZ resistance are not well understood. The known resistance mutation F200Y is present in both *tbb-1* and *tbb-2*. However, this mutation is hypothesized to cause a change in BZ binding and not loss of gene function. All of the other beta-tubulin genes lack known resistance-associated alleles and should be inhibited by BZs. So far, validated *ben-1* resistance mutations have been phenotypically equivalent to a loss of *ben-1* in *C. elegans*, so we generated loss-of-function deletions of each beta-tubulin. We compared the effects of single beta-tubulin deletions on nematode development when

exposed to a single concentration of ABZ that previously was found to confer a significant impact on the larval development of the wild-type N2 strain of *C. elegans* (Dilks et al., 2020, 2021; Pallotto et al., 2022). We found that the loss of *ben-1* conferred the highest level of resistance and the loss of *tbb-1* conferred moderate resistance. To test for genetic redundancy among beta-tubulin genes, we used CRISPR-Cas9 genome editing to delete each beta-tubulin gene in a genetic background that already has lost *ben-1* function. The loss of each beta-tubulin gene in the *ben-1* deletion background did not confer a detectable change in ABZ resistance compared to the loss of *ben-1* alone. Overall, we find that the loss of *ben-1* alone is sufficient to confer the maximum level of ABZ resistance at the concentration tested, with development equivalent to the wild-type strain in control conditions.

## 2. Materials and methods

### 2.1. *C. elegans* strains and maintenance

Nematodes were grown on plates of modified nematode growth media (NGMA) containing 1% agar and 0.7% agarose and seeded with the *Escherichia coli* strain OP50 (Andersen et al., 2014). Plates were maintained at 20 °C for the duration of all experiments. Before each assay, animals were grown for three generations to reduce the multi-generational effects of starvation.


CRISPR-Cas9-edited strains were generated as previously described (Hahnel et al., 2018; Dilks et al., 2020) (S1 Table), except for VC364 *tbb-1(gk207)*, which was acquired from the *Caenorhabditis* Genetics Center (Minneapolis, MN). All single deletions were generated in the reference N2 genetic background. All double deletions were generated in the ECA882 *ben-1(ean64)* genetic background (Dilks et al., 2020, 2021). Progeny from injected animals (F1) were individually placed onto NGMA plates to reproduce and then sequenced using Sanger sequencing to confirm the presence of the desired edit. At least two generations of animals after single-animal passage were Sanger sequenced to confirm successful genome edits. Two independent strains of each deletion and pair of deletions were generated to control for any potential off-target effects caused by CRISPR-Cas9 (Fig. 1).

### 2.2. Nematode food preparation

The OP50 strain of *E. coli* was used as a nematode food source on NGMA plates. Bacterial food for the liquid-based high-throughput assay was prepared as previously described (Widmayer et al., 2022). Briefly, a frozen stock of the HB101 strain of *E. coli* was used to inoculate and grow a 1 L culture to an OD<sub>600</sub> value of 0.001. HB101 was used for all liquid-based imaging assays because it grows faster than OP50 and should provide better nutrition for *C. elegans* (Fox et al., 2022). Six cultures containing 1 L of pre-warmed 1x Horvitz Super Broth (HSB) and an OD<sub>600</sub> inoculum grew for 15 h at 37 °C until cultures were in the late log growth phase. After 15 h, flasks were removed from the incubator and transferred to 4 °C to halt bacterial growth. Cultures were pelleted using centrifugation, the supernatant removed, and washed with K medium (51 mM NaCl, 32 mM KCl, 3 mM CaCl<sub>2</sub>, and 3 mM MgSO<sub>4</sub> in distilled water) (Boyd et al., 2012). Bacteria were resuspended in K medium, and the OD<sub>600</sub> value was determined. The bacterial suspension was diluted to a final concentration of OD<sub>600</sub>100 before being aliquoted to 30 mL and frozen at -80 °C.

### 2.3. Albendazole stock preparation

A 100 μM stock solution of albendazole (Fluka, Catalog #: A4673-10G) was prepared in dimethyl sulfoxide (DMSO), aliquoted, and stored at -20 °C. A frozen ABZ aliquot was thawed shortly before adding the drug to the assay plates.



**Fig. 1. Gene models and locations of deletion alleles generated in *C. elegans* beta-tubulin genes.** Gene models of the longest isoforms are presented for each *C. elegans* beta-tubulin gene, with exons (orange), introns (gray lines), and untranslated regions (gray boxes) shown. Regions that were deleted using CRISPR-Cas9 genome editing are shown as black lines under each model. Deleted regions of *tbb-1* are shown as two black lines because strains with two independent deletion alleles were used. Gene model data were obtained from WormBase (WS279). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

#### 2.4. High-throughput phenotyping assay (HTA)


A previously described HTA was used for all ABZ response phenotyping assays (Shaver et al., 2023). Two independent assays made up of three bleaches each were performed. Strains underwent three generations of growth to control for any starvation effects and were then bleach synchronized in triplicate to control for variation caused by bleach effects. Embryos were concentrated at 0.6 embryos/ $\mu\text{L}$  in 50  $\mu\text{L}$  of K medium (Boyd et al., 2012). A volume of 50  $\mu\text{L}$  of the embryo solution was dispensed into each well of a 96-well plate. Both DMSO and ABZ conditions contained 48 wells of N2 and ECA882, and 24 wells of each of the other tested strains for each replicate bleach. Embryos were allowed to hatch overnight at 20  $^{\circ}\text{C}$  with constant shaking at 180 rpm. The following morning, HB101 aliquots were thawed at room temperature, combined, and diluted to  $\text{OD}_{600}30$  with K medium, and kanamycin was added at a concentration of 150  $\mu\text{M}$  to inhibit further bacterial growth and prevent contamination. The final well concentration of HB101 was  $\text{OD}_{600}10$ , and the final concentration of kanamycin was 50  $\mu\text{M}$ . Each well was treated with a final concentration of either 1% DMSO or 30  $\mu\text{M}$  ABZ in 1% DMSO. Animals were grown for 48 h with constant shaking at 180 rpm, after which, animals were treated with 50 mM sodium azide in M9 buffer to straighten and paralyze the animals for imaging. Following 10 min of exposure to sodium azide, each plate was imaged using a Molecular Devices ImageXpress Nano microscope (Molecular Devices, San Jose, CA) with a 2X objective (Shaver et al., 2023).

Independent assays included identical strain sets except as follows: Strains with a deletion of *tbb-2* were found to be too developmentally delayed to use in these assays. The ECA3726 *ben-1(ean64)*; *mec-7(ean257)* strain was removed from assay one because of an insufficient quantity of embryos after bleach synchronization. Smaller significant effects on animal development were observed for some single deletions


in control conditions of assay one but not in assay two, indicating that significance assigned to the observed small effects could be the result of high levels of replication, making even small differences significant.

#### 2.5. Data cleaning and analysis

High-throughput assay images were processed using CellProfiler (<https://github.com/AndersenLab/CellProfiler>). Processed image data were cleaned and processed using the *easyXpress* (Nyaanga et al., 2021) R package as previously described (Shaver et al., 2024). The two assays were cleaned and processed independently. All statistical comparisons and figure generation were performed in R(4.1.2) (R Core Team, 2020). Median animal lengths were calculated from each well of an assay plate and normalized across independent growths, plates, and bleaches. Deletion of each beta-tubulin gene in the same genetic background enables the determination of the quantitative effects that each gene has on BZ response, as well as to determine if the loss of each beta-tubulin gene impacts development in control conditions. Median animal length after 48 h of exposure was normalized to control conditions, and then statistical comparisons were made between N2 and each strain. We used the *Rstatix* package *tukeyHSD* function on an ANOVA model generated with the formula *phenotype* ~ *strain* to calculate differences in the responses of the strains. Fig. 2 was generated using data from assay one because of the large amount of variation shown in animal response for the VC364 *tbb-1(gk207)* strain in assay two (S1 Figure), thought to be caused by human error. Fig. 3 was generated using data from assay two, because of the loss of the ECA3746 strain in assay one. All data are presented in supplemental figures.



**Fig. 2. Only loss of *ben-1* causes high levels of resistance to ABZ.** Median animal lengths of strains grown in 30  $\mu$ M ABZ that have been regressed for bleach effects and then normalized to the mean of all median animal lengths from the control condition are shown. Each point represents the summarized measurements of an individual well containing five to 30 animals. Data are shown as box plots with the median as a solid horizontal line and the 75th and 25th quartiles on the top and bottom of the box, respectively. The top and bottom whiskers extend to the maximum point within the 1.5 interquartile range from the 75th and 25th quartiles, respectively. Statistical significance compared to the wild-type strain is shown above each strain ( $p < 0.05 = *$ ,  $p < 0.0001 = ****$ , ANOVA with Tukey HSD).



**Fig. 3. None of the other beta-tubulin genes act redundantly with *ben-1* in ABZ response.** Median animal lengths of strains grown in 30  $\mu$ M ABZ that have been regressed for bleach effects and then normalized to the mean of all median animal lengths from the control condition are shown. Each point represents the summarized measurements of an individual well containing five to 30 animals. Data are shown as box plots with the median as a solid horizontal line and the 75th and 25th quartiles on the top and bottom of the box, respectively. The top and bottom whiskers extend to the maximum point within the 1.5 interquartile range from the 75th and 25th quartiles, respectively. Statistical significance compared to the *ben-1* deletion strain is shown above each strain ( $p < 0.05 = *$ ,  $p < 0.0001 = ****$ , ANOVA with Tukey HSD).

### 3. Results

#### 3.1. The loss of *ben-1* is the only beta-tubulin gene to confer high levels of ABZ resistance

CRISPR-Cas9 genome editing was used to generate deletions of each beta-tubulin gene in the N2 laboratory strain genetic background (Fig. 1). Edited strains with single deletions of each beta-tubulin gene were phenotyped in DMSO (control) and ABZ using a previously described high-throughput assay (HTA) that quantitatively measures nematode development (Widmayer et al., 2022; Shaver et al., 2023). The loss of *tbb-1* had the most significant impact on development in control conditions, indicating that the loss of *tbb-1* is possibly detrimental (S2 Figure). The loss of *ben-1* was the only strain to confer high levels of resistance to ABZ, with development in ABZ conditions equivalent to that of the wild-type strain in control conditions (Fig. 2, S3

Figure). The loss of *tbb-1* was found to confer a moderate level of resistance, with animal development significantly less affected than the wild-type strain but still heavily affected by ABZ as compared to growth in control conditions.

#### 3.2. The loss of *ben-1* confers the highest level of ABZ resistance compared to other beta-tubulin mutants

To determine if other beta-tubulin genes play a redundant role in ABZ resistance with *ben-1*, we generated individual deletions of *tbb-1*, *mec-7*, *tbb-4*, and *tbb-6* in the *ben-1(ean64)* genetic background. We exposed these double beta-tubulin mutants to DMSO and ABZ in the same high-throughput development assay described above to determine if the loss of a second beta-tubulin alters the levels of BZ resistance observed in the single *ben-1* mutant. Similarly to the single deletion assay, small significant differences were observed for multiple strains



compared to the wild-type strain in control conditions, except for the strain ECA3628 *ben-1(ean64); tbb-4(ean282)* (S4 Figure), which was found to be more heavily impacted in both replicate assays. Strains with the loss of a second beta-tubulin were found to be equally resistant when compared to the loss of *ben-1* alone (Fig. 3, S5 Figure). As previously noted, the loss of *ben-1* almost fully rescued development at 30  $\mu$ M ABZ compared to the control strain, possibly preventing any small effects conferred by the loss of a second beta-tubulin from being observed.

#### 4. Discussion

Despite the established role variants in *ben-1* orthologs have in BZ resistance, differential responses of *C. elegans* wild strains highlight that additional genes must be involved in BZ response (Hahnel et al., 2018; Zamanian et al., 2018). Fully understanding the mechanisms of BZ resistance is imperative to the development of strategies to promote the sustainability of BZ anthelmintics, because an understanding of all genes involved provides multiple potential targets of treatment, limiting the development of resistance. Here, we took an important first step to test additional beta-tubulin genes in BZ resistance.

##### 4.1. *ben-1* plays the largest role in ABZ resistance in *C. elegans*

We examined the role that five of the six *C. elegans* beta-tubulin genes play in ABZ resistance by generating strains with a loss of each gene, as well as strains with a loss of an additional beta-tubulin in a *ben-1* mutant background. Because of detrimental effects on development, strains with a loss of *tbb-2* could not be measured for responses to ABZ. Consistent with previous studies, the loss of *ben-1* was sufficient to confer the maximum level of ABZ resistance at a concentration of 30  $\mu$ M. Although *tbb-1(gk207)* demonstrated a lower level of resistance compared to the *ben-1* deletion strain, and was negatively impacted in control conditions, it is possible that other background mutations could cause resistance (and slower growth in control conditions) because this strain was not backcrossed. Loss of a second beta-tubulin in a strain with a loss of *ben-1* did not confer a detectable enhancement of resistance, and with the exception of the ECA3628 *ben-1(ean64); tbb-4(ean282)* strain, did not confer severe detriment in control conditions. The ECA3628 strain could have unintended off-target effects caused by gene editing that reduced fitness, because the effect is seen in both replicate assays but is not seen in the second independent edit strain with deletions of both *ben-1* and *tbb-4*. Despite observing no effects from the deletion of a second beta-tubulin, we cannot definitively conclude if any other beta-tubulin gene acts redundantly with *ben-1* in ABZ resistance. The assay that we used to measure ABZ resistance uses one concentration that previously was found to differentiate susceptible strains from *ben-1* mutant strains (Dilks et al., 2020, 2021). It remains possible that enhancement of ABZ resistance could be detected at higher ABZ concentrations where the single contribution of *ben-1* might not be sufficient to cause resistance alone. Another caveat is that only a single trait, development, was measured. ABZ affects multiple traits, including fecundity and competitive fitness over multiple generations (Shaver et al., 2024). Future studies should investigate multiple traits at different ABZ concentrations to fully understand the role of all beta-tubulin genes in the ABZ response.

##### 4.2. BZ resistance is complicated by differences in beta-tubulin copy number, levels of expression, and resistance alleles

We tested the role of each beta-tubulin gene in ABZ response by deleting much of the coding sequence. Therefore, these results are binary for the presence or absence of each beta-tubulin gene. Amino-acid altering variants from parasites have been validated in ABZ resistance using *C. elegans* and shown to cause ABZ resistance equivalent to a strain with a loss of *ben-1* (Dilks et al., 2020, 2021; Venkatesan et al., 2023). However, these variants likely do not cause loss of *tbb-isotype-1* function in parasites (Saunders et al., 2013). What could be causing this

discrepancy between loss-of-function variants in *C. elegans* and potential altered function variants in parasitic nematodes? In species with highly expressed beta-tubulin genes that have BZ-sensitive alleles, loss-of-function alleles would cause fitness defects, similar to what we see with the deletion of *tbb-1* and *tbb-2*. In these species, BZ resistance must be mediated by altered function variants. In species with less highly expressed (or tissue-specific) beta-tubulin genes that have BZ-sensitive alleles, loss-of-function alleles could cause BZ resistance because other beta-tubulin genes can substitute for essential functions, similar to what is observed in *C. elegans* with *ben-1*. Interestingly, although loss-of-function alleles in *tbb-isotype-1* are thought to be lethal, the loss of the *H. contortus* beta-tubulin gene *tbb-isotype-2* has been documented in some highly resistant *H. contortus* populations, possibly amplifying the resistance conferred by mutations in *tbb-isotype-1* alone (Saunders et al., 2013). However, variation in *tbb-isotype-2* alone is likely not sufficient to cause resistance, and to our knowledge, resistance associated with variation in *tbb-isotype-2* has not been documented independent of variation in *tbb-isotype-1*. The whole-organism expression levels of *tbb-isotype-2* are less than half that of *tbb-isotype-1* likely explaining why variation in *tbb-isotype-1* is necessary for resistance and further highlighting the role that differences in expression can play when combined with change- or loss-of-function variants. Additionally, the phenotypic classification of BZ-resistance phenotypes differs between these two species and can be explained by differences in loss-of-function vs. altered function mutations. In *C. elegans* where *ben-1* variants or mutations can cause loss of function, the BZ-resistance phenotype is recessive (Dilks et al., 2021). By contrast, putative BZ-resistance alleles in *H. contortus* are hypothesized to confer incomplete dominance where heterozygotes are somewhat resistant and homozygotes are fully resistant (Silvestre et al., 2001).

Beyond coding variants or mutations in beta-tubulin genes, changes in the levels and tissue-specific expression can alter BZ resistance. Previously, we found that some *C. elegans* wild strains with clear ABZ resistance, when compared to the laboratory N2 strain, do not have variants that alter the coding sequence of *ben-1* but instead have much lower expression levels of *ben-1* as compared to the rest of the population (Zhang et al., 2022). These strains are resistant because the susceptible beta-tubulin protein is not expressed. Additionally, we found that the expression of *ben-1* in cholinergic neurons alone is sufficient to confer susceptibility to ABZ (Gibson et al., 2022), highlighting that variants modifying expression in specific tissues could confer resistance in a unique way independent of the beta-tubulin coding sequence. These observations from both *C. elegans* and *H. contortus* demonstrate that more attention should be paid to the number of beta-tubulin genes, their levels of expression, the sites of expression, and the putative BZ-resistance alleles found in each beta-tubulin gene. To definitively understand BZ resistance mediated by beta-tubulin genes, we must also drastically improve parasitic nematode genomes and gene models because most species lack full descriptions of their beta-tubulin complement.

#### 5. Future directions

The role of *ben-1* and *tbb-isotype-1* beta-tubulins in BZ resistance has been thought to be similar and established *C. elegans* as an essential model for parasite BZ resistance research. However, BZ treatment is typically fatal in susceptible parasites (Prichard, 1988), as well as documented ovicidal effects of BZs against parasite embryos (Boes et al., 1998). Conversely, the same effects are not typically seen in *C. elegans* where the most significant impact is often on the developmental rate (Shaver et al., 2023). The loss of *tbb-1* or *tbb-2* was deleterious and loss-of-function mutations in either gene would likely be rapidly selected against in the wild (i.e., no variants are observed in natural *C. elegans* strains) (Crombie et al., 2024), similarly to the predicted loss of *tbb-isotype-1*. It is important to note that *tbb-1* and *tbb-2* have known resistance alleles at amino acid position 200, and future studies should

edit both genes to make them harbor BZ-sensitive alleles to more closely approximate the beta-tubulin complement and alleles in *H. contortus*. Such studies could offer an improved model system for investigating BZ resistance. However, studies of BZ resistance need to investigate variants beyond single amino-acid alterations. Our results from previous publications demonstrate that a variety of factors such as copy number, expression, and tissue-specific function can all affect BZ resistance. To continue to broaden our understanding of BZ resistance, we must expand to a whole-genome approach that investigates variants across every single beta-tubulin gene and beyond that single class of genes.

## Data availability

All code and data are available at [https://github.com/AndersenLab/2024\\_beta\\_tubulin\\_manuscript](https://github.com/AndersenLab/2024_beta_tubulin_manuscript).

## Funding sources

Skyler Stone, Fiona Shao, and Gracie Paredes were funded by Northwestern University Summer Undergraduate Research Grants. Skyler Stone was also funded by the Posner Research Program at Northwestern University. This work was supported by the National Institutes of Health NIAID grant R01AI153088 to ECA.

## CRedit authorship contribution statement

**J.B. Collins:** Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Skyler A. Stone:** Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Emily J. Koury:** Resources, Methodology, Investigation. **Anna G. Paredes:** Resources, Investigation. **Fiona Shao:** Resources, Investigation. **Crystal Lovato:** Resources, Investigation. **Michael Chen:** Resources, Investigation. **Richelle Shi:** Resources, Investigation. **Anwyn Y. Li:** Resources, Investigation. **Isa Candal:** Resources, Investigation. **Khadija Al Moutaa:** Resources, Investigation. **Nicolas D. Moya:** Methodology, Investigation, Formal analysis. **Erik C. Andersen:** Writing – review & editing, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization.

## Declaration of competing interest

None.

## Acknowledgments

We would like to thank members of the Andersen lab for their feedback in the preparation of this manuscript. We thank the *Caenorhabditis* Natural Diversity Resource (NSF Capacity Grant 2224885) and the *Caenorhabditis* Genetics Center (NIH Office of Research Infrastructure Programs, P40 OD010440) for providing the strains used in this study. Additionally, we would also like to thank WormBase for providing an essential resource for genetic and genomic data used in this manuscript.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijpddr.2024.100556>.

## References

Andersen, E.C., Bloom, J.S., Gerke, J.P., Kruglyak, L., 2014. A variant in the neuropeptide receptor npr-1 is a major determinant of *Caenorhabditis elegans* growth and physiology. *PLoS Genet.* 10, e1004156.  
Avramenko, R.W., Redman, E.M., Melville, L., Bartley, Y., Wit, J., Queiroz, C., Bartley, D. J., Gilleard, J.S., 2019. Deep amplicon sequencing as a powerful new tool to screen

for sequence polymorphisms associated with anthelmintic resistance in parasitic nematode populations. *Int. J. Parasitol.* 49, 13–26.  
Banerjee, S., Mukherjee, S., Nath, P., Mukherjee, A., Mukherjee, S., Ashok Kumar, S.K., De, S., Banerjee, S., 2023. A critical review of benzimidazole: sky-high objectives towards the lead molecule to predict the future in medicinal chemistry. *Results in Chemistry* 6, 101013.  
Boes, J., Eriksen, L., Nansen, P., 1998. Embryonated and infectivity of *Ascaris suum* eggs isolated from worms expelled by pigs treated with albendazole, pyrantel pamoate, ivermectin or piperazine dihydrochloride. *Vet. Parasitol.* 75, 181–190.  
Boyd, W.A., Smith, M.V., Freedman, J.H., 2012. *Caenorhabditis elegans* as a model in developmental toxicology. In: Harris, C., Hansen, J.M. (Eds.), *Developmental Toxicology: Methods and Protocols*. Humana Press, Totowa, NJ, pp. 15–24.  
Chalfie, M., Thomson, J.N., 1982. Structural and functional diversity in the neuronal microtubules of *Caenorhabditis elegans*. *J. Cell Biol.* 93, 15–23.  
Crombie, T.A., McKeown, R., Moya, N.D., Evans, K.S., Widmayer, S.J., LaGrassa, V., Roman, N., Tursunova, O., Zhang, G., Gibson, S.B., Buchanan, C.M., Roberto, N.M., Vieira, R., Tanny, R.E., Andersen, E.C., 2024. CaenNDR, the *Caenorhabditis* natural diversity resource. *Nucleic Acids Res.* 52, D850–D858.  
Dilks, C.M., Hahnel, S.R., Sheng, Q., Long, L., McGrath, P.T., Andersen, E.C., 2020. Quantitative benzimidazole resistance and fitness effects of parasitic nematode beta-tubulin alleles. *Int. J. Parasitol. Drugs Drug Resist.* 14, 28–36.  
Dilks, C.M., Koury, E.J., Buchanan, C.M., Andersen, E.C., 2021. Newly identified parasitic nematode beta-tubulin alleles confer resistance to benzimidazoles. *Int. J. Parasitol. Drugs Drug Resist.* 17, 168–175.  
Driscoll, M., Dean, E., Reilly, E., Bergholz, E., Chalfie, M., 1989. Genetic and molecular analysis of a *Caenorhabditis elegans* beta-tubulin that conveys benzimidazole sensitivity. *J. Cell Biol.* 109, 2993–3003.  
Fox, B.W., Ponomarova, O., Lee, Y.-U., Zhang, G., Giese, G.E., Walker, M., Roberto, N.M., Na, H., Rodrigues, P.R., Curtis, B.J., Kolodziej, A.R., Crombie, T.A., Zdraljevic, S., Yilmaz, L.S., Andersen, E.C., Schroeder, F.C., Walhout, A.J.M., 2022. C. elegans as a model for inter-individual variation in metabolism. *Nature* 607, 571–577.  
Gibson, S.B., Ness-Cohn, E., Andersen, E.C., 2022. Benzimidazoles cause lethality by inhibiting the function of *Caenorhabditis elegans* neuronal beta-tubulin. *Int. J. Parasitol. Drugs Drug Resist.* 20, 89–96.  
Hahnel, S.R., Zdraljevic, S., Rodriguez, B.C., Zhao, Y., McGrath, P.T., Andersen, E.C., 2018. Extreme allelic heterogeneity at a *Caenorhabditis elegans* beta-tubulin locus explains natural resistance to benzimidazoles. *PLoS Pathog.* 14, e1007226.  
Hastie, A.C., Georgopoulos, S.G., 1971. Mutational resistance to fungitoxic benzimidazole derivatives in *Aspergillus nidulans*. *J. Gen. Microbiol.* 67, 371–373.  
Howell, S.B., Burke, J.M., Miller, J.E., Terrill, T.H., Valencia, E., Williams, M.J., Williamson, L.H., Zajac, A.M., Kaplan, R.M., 2008. Prevalence of anthelmintic resistance on sheep and goat farms in the southeastern United States. *J. Am. Vet. Med. Assoc.* 233, 1913–1919.  
Hurd, D.D., 2018. Tubulins in *C. elegans*. *WormBook*.  
Kaplan, R.M., 2004. Drug resistance in nematodes of veterinary importance: a status report. *Trends Parasitol.* 20, 477–481.  
Kitchen, S., Ratnapan, R., Han, S., Leasure, C., Grill, E., Iqbal, Z., Granger, O., O'Halloran, D.M., Hawdon, J.M., 2019. Isolation and characterization of a naturally occurring multidrug-resistant strain of the canine hookworm, *Ancylostoma caninum*. *Int. J. Parasitol.* 49, 397–406.  
Krücken, J., Fraundorfer, K., Mugisha, J.C., Ramünke, S., Sift, K.C., Geus, D., Habarugira, F., Ndoli, J., Sendegeya, A., Mukampunga, C., Bayingana, C., Aebischer, T., Demeler, J., Gahutu, J.B., Mockenhaupt, F.P., von Samson-Himmelstjerna, G., 2017. Reduced efficacy of albendazole against *Ascaris lumbricoides* in Rwandan schoolchildren. *Int. J. Parasitol. Drugs Drug Resist.* 7, 262–271.  
Kwa, M.S., Kooyman, F.N., Boersema, J.H., Roos, M.H., 1993. Effect of selection for benzimidazole resistance in *Haemonchus contortus* on beta-tubulin isotype 1 and isotype 2 genes. *Biochem. Biophys. Res. Commun.* 191, 413–419.  
Kwa, M.S., Veenstra, J.G., Roos, M.H., 1994. Benzimidazole resistance in *Haemonchus contortus* is correlated with a conserved mutation at amino acid 200 in beta-tubulin isotype 1. *Mol. Biochem. Parasitol.* 63, 299–303.  
Kwa, M.S., Veenstra, J.G., Van Dijk, M., Roos, M.H., 1995. Beta-tubulin genes from the parasitic nematode *Haemonchus contortus* modulate drug resistance in *Caenorhabditis elegans*. *J. Mol. Biol.* 246, 500–510.  
Mohammedsalih, K.M., Krücken, J., Khalafalla, A., Bashar, A., Juma, F.-R., Abakar, A., Abdalmalaik, A.A.H., Coles, G., von Samson-Himmelstjerna, G., 2020. New codon 198 beta-tubulin polymorphisms in highly benzimidazole resistant *Haemonchus contortus* from goats in three different states in Sudan. *Parasit. Vectors* 13, 114.  
Nyaanga, J., Crombie, T.A., Widmayer, S.J., Andersen, E.C., 2021. easyXpress: an R package to analyze and visualize high-throughput C. elegans microscopy data generated using CellProfiler. *PLoS One* 16, e0252000.  
Pallotto, L.M., Dilks, C.M., Park, Y.J., Smit, R.B., Lu, B.T., Gopalakrishnan, C., Gilleard, J. S., Andersen, E.C., Mains, P.E., 2022. Interactions of *Caenorhabditis elegans* beta-tubulins with the microtubule inhibitor and anthelmintic drug albendazole. *Genetics* 221 (4), iyac093.  
Prichard, R.K., 1988. Anthelmintics and control. *Vet. Parasitol.* 27, 97–109.  
R Core Team, 2020. R: A Language and Environment for Statistical Computing.  
Salikin, N.H., Nappi, J., Majzoub, M.E., Egan, S., 2020. Combating parasitic nematode infections, newly discovered antinematode compounds from marine epiphytic bacteria. *Microorganisms* 8. <https://doi.org/10.3390/microorganisms8121963>.  
Saunders, G.I., Wasmuth, J.D., Beech, R., Laing, R., Hunt, M., Naghra, H., Cotton, J.A., Berriman, M., Britton, C., Gilleard, J.S., 2013. Characterization and comparative analysis of the complete *Haemonchus contortus* beta-tubulin gene family and implications for benzimidazole resistance in strongylid nematodes. *Int. J. Parasitol.* 43, 465–475.

- Shaver, A.O., Miller, I.R., Schaye, E.S., Moya, N.D., Collins, J.B., Wit, J., Blanco, A.H., Shao, F.M., Andersen, E.J., Khan, S.A., Paredes, G., Andersen, E.C., 2024. Quantifying the fitness effects of resistance alleles with and without anthelmintic selection pressure using *Caenorhabditis elegans*. *PLoS Pathog.* 20 (5), e1012245.
- Shaver, A.O., Wit, J., Dilks, C.M., Crombie, T.A., Li, H., Aroian, R.V., Andersen, E.C., 2023. Variation in anthelmintic responses are driven by genetic differences among diverse *C. elegans* wild strains. *PLoS Pathog.* 19, e1011285.
- Sheir-Neiss, G., Lai, M.H., Morris, N.R., 1978. Identification of a gene for beta-tubulin in *Aspergillus nidulans*. *Cell* 15, 639–647.
- Silvestre, A., Cabaret, J., Humbert, J.F., 2001. Effect of benzimidazole under-dosing on the resistant allele frequency in *Teladorsagia circumcincta* (Nematoda). *Parasitology* 123, 103–111.
- Venkatesan, A., Jimenez Castro, P.D., Morosetti, A., Horvath, H., Chen, R., Redman, E., Dunn, K., Collins, J.B., Fraser, J.S., Andersen, E.C., Kaplan, R.M., Gilleard, J.S., 2023. Molecular evidence of widespread benzimidazole drug resistance in *Ancylostoma caninum* from domestic dogs throughout the USA and discovery of a novel  $\beta$ -tubulin benzimidazole resistance mutation. *PLoS Pathog.* 19, e1011146.
- Widmayer, S.J., Crombie, T.A., Nyaanga, J.N., Evans, K.S., Andersen, E.C., 2022. *C. elegans* toxicant responses vary among genetically diverse individuals. *Toxicology* 479, 153292.
- Wit, J., Dilks, C.M., Andersen, E.C., 2021. Complementary approaches with free-living and parasitic nematodes to understanding anthelmintic resistance. *Trends Parasitol.* 37, 240–250.
- Zamanian, M., Cook, D.E., Zdraljjevic, S., Brady, S.C., Lee, D., Lee, J., Andersen, E.C., 2018. Discovery of genomic intervals that underlie nematode responses to benzimidazoles. *PLoS Neglected Trop. Dis.* 12, e0006368.
- Zhang, G., Roberto, N.M., Lee, D., Hahnel, S.R., Andersen, E.C., 2022. The impact of species-wide gene expression variation on *Caenorhabditis elegans* complex traits. *Nat. Commun.* 13, 3462.